Shengda Network Technology, Inc. provides portals for the sale of products offered by various manufacturers and merchants. It offers electronics, daily consumable products, food, and clothing. The company was formerly known as Soltrest Inc. Shengda Network Technology Inc. was incorporated in 2018 and is based in Jinhua, China.

Tuff Group AG engages in the oil and gas, infrastructure, and energy fields. It provides engineering, procurement, construction, installation, and commissioning services to the oil and gas, and energy sector, as well as offers related operations and maintenance services. The company also engages in planning, designing, and engineering activities; consulting and construction management; and project management business in areas of roads, bridges, highways, inland waterways, ports and terminals, real estate and resorts development, water and wastewater treatment, and affordable housing. In addition, it acts as a general contractor for infrastructure projects. The company was founded in 2015 and is headquartered in Singapore.

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Champion Iron Limited engages in the acquisition, exploration, development, and production of iron ore deposits in North-Eastern Quebec. Its flagship project include the Bloom Lake mine, which consists of BM877 mining lease covering an area of 6,857.63 ha and 53 mining claims comprising an area of approximately 2,458.29 ha located in Quebec, Canada; and the Consolidated Fire Lake North project that includes the Fire Lake North, Don Lake, Bellechasse, and Oil Can deposits situated in northeastern Quebec. The company was formerly known as Champion Iron Mines Limited and changed its name to Champion Iron Limited in March 2014. Champion Iron Limited is headquartered in Rozelle, Australia.

Genesis Minerals Limited engages in the exploration and development of gold deposits in Western Australia. The company owns 100% interests in the Ulysses Gold project located to the north of Kalgoorlie. Genesis Minerals Limited was incorporated in 2007 and is based in West Perth, Australia.

Medivolve Inc. is a principal investment firm. It is a social-impact investment focused company Investing resources, funds and bandwidth for the betterment of the human condition through medical sciences, climate change and technology. The firm was formerly known as Continent Resources Inc. and changed its name to Copper One Inc. in October 2009. Copper One Inc. was incorporated in 2005 and is headquartered in Toronto, Canada.

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Venturex Resources Limited, together with its subsidiaries, engages in the exploration and development of mineral resources in Australia. It primarily explores for copper, zinc, lead, silver, and gold deposits. The company's flagship project is the Sulphur Springs project that includes Sulphur Springs and Kangaroo Caves deposits and tenements located to the south east of Port Hedland. Venturex Resources Limited was incorporated in 2006 and is based in West Perth, Australia.

Element 25 Limited engages in the exploration of mineral properties in Australia and France. The company explores for manganese, copper, and nickel deposits. It owns a 100% interest in the Butcherbird manganese project for producing high purity manganese sulphate monohydrate for use in lithium-ion battery. The company's Butcherbird project is located to the north of Perth and south of Newman in the Pilbara region, Western Australia. It also holds 100% interest in the Pinnacles project located to the northeast of Kalgoorlie. The company was formerly known as Montezuma Mining Company Limited and changed its name to Element 25 Limited in May 2018. Element 25 Limited was incorporated in 2006 and is based in Osborne Park, Australia.

Capricorn Metals Ltd explores for, evaluates, and develops mineral properties in Australia and Madagascar. It holds a 100% interest in the Karlawinda gold project located in the Pilbara region of Western Australia. The company was formerly known as Malagasy Minerals Limited and changed its name to Capricorn Metals Limited in February 2016. Capricorn Metals Limited was incorporated in 2006 and is based in West Perth, Australia.